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Abstract. This study was designed to evaluate the hepatoprotective activity of the seeds of Hunteria umbellata (HU) on 
carbon tetrachloride (CCl4) induced rats. Rats of groups 1 (normal control), 3 and 5 were not treated with CCl4 while rats 
of groups 2 (negative control), 4 and 6 rats were treated with single dose of CCl4 (2 ml/kg) by intraperitoneal administration. 
Normal control group 1 rats were given distilled water, groups 3 and 4 rats were given 50 mg/kg of silymarin while groups 
5 and 6 rats were given 500 mg/kg of HU. Treatment was administered orally for 28 days and sacrificed on the 29th day 
after an overnight fast. The weights of the rats were taken before and after the treatment. Blood samples were collected in 
heparinized tubes and biochemical analysis of liver functions and lipid profile tests were carried out on plasma. There was 
a significant change (p<0.05) in the levels of alanine aminotransferase, alkaline phosphatase, high density lipoprotein and 
triglycerides of the CCl4 induced group treated with HU compared to the CCl4 untreated group 2 animals. The results 
obtained showed that the ethanolic extract of HU has hepatoprotective property. 
INTRODUCTION 
The liver is a largest grandular organ in the body known for performing important functions such as metabolism, 
detoxification, digestion, storage and synthesis. Even though, the hepatocytes have a remarkable regenerative capacity, 
constant exposure to toxicants will eventually lead to hepatotoxicity. Some of the toxicants previously reported are 
carbon tetrachloride (CCl4), acetaminophen, nitrosamines and polycyclic aromatic hydrocarbons [1] CCl4 is a classic 
hepatotoxin that causes hepatic failure and commonly used as solvents and most especially in fire extinguishers thus 
leading to human exposure through inhalation [2]. In CCl4-induced hepatotoxicity, liver damage is majorly caused by 
haloalkylation and lipid peroxidation [3]. These mechanisms involve the production of radicals which covalently bind 
macromolecules including proteins, nucleic acids and lipids thus leading to changes in the structures of these 
biomolecules [4]. On activation, CCl4 affects both synthesis and degradation of lipids leading to accumulation of fat, 
a major consequence generally seen in CCL4-induced hepatotoxicity. CCl4 inhibits triacylglycerol synthesis and also 
play a part in impairing the movement of triacylglycerol through very low density lipoprotein (VLDL) [5]. 
Hunteria umbellate from the family Apocynaceae is a plant known for its efficacy in treating various ailments. The 
small plant thrives well in the tropical regions of West Africa and popularly known as Aadaci by the Hausas, Mkpokiri 
by Igbos and Abere by Yorubas [6]. Various parts of the plant have been explored for medicinal values and have been 
reported to be efficient in treating different diseases like diabetes [7]. Seeds of this plant are of high value with 
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hypolipidemic, weight losing, antihyperlipidemic, hypoglycemic and cardioprotective properties [8, 9, 10]. Even 
though many studies have shown the efficacy of different parts of this plant, seeds of the plant is yet to be explored 
for potential benefits. This study is focused on the effects of the seeds of H umbellate on hepatotoxicity. 
MATERIALS AND METHODS 
Plant 
Already dried and grounded seeds of Hunteria umbellata plant were obtained from previous studies. Botancial 
identification was done by Dr. O.O. Ogunlana, Covenant University, Ota, Ogun state Nigeria. 
Experimental Animals 
Animals of an average weight of 150 g were divided into six experimental groups and housed under standard 
condition exposing them to 12-hour light and dark cycle. Animals were allowed to acclimatise for two weeks before 
the commencement of the experiment. All the animal experiment and handling were carried according to standard 
protocols approved by the animal ethics committee of the department of Biochemistry, Covenant University, Ota, 
Ogun State Nigeria. 
Experimental Design 
Thirty-six (36) experimental animals were divided into six groups of six animals each and were weighed weekly 
throughout the duration of the study. A modification of the hepatoprotective effect on rats as described by Murugesan 
et al. [11], Adebayo et al. [12] and Adebayo et al. [13] were adopted in this experimental study. 
Animals in groups 1 (Normal control), 3 (Silymarin control) and 5 (AP control) were given through gastric 
intubation, distil water (1 ml/Kg body weight), silymarin (50 mg/kg body weight) and H. umbellata (500 mg/kg body 
weight) respectively for 28 days and thereafter given intraperitoneal injection of normal saline and olive oil (1 ml/Kg 
body weight). While animals in groups 2 (Negative control), 4 (silymarin + CCl4) and 6 (H. umbellata + CCl4) were 
given through oral route, distil water (1 ml/Kg body weight), silymarin (50 mg/kg body weight) and H. umbellata 
(500mg/kg body weight) respectively for 28 days and thereafter followed by a single intraperitoneal injection of CCl4 
in olive oil (2 ml/kg bodyweight). After 24 hours of intraperitoneal injection and overnight fast, all the animals were 
sacrificed by methods previously described by Ogunlana et al. [14], Ogunlana et al. [15] and Ogunlana et al. [16] 
Biochemical Analysis 
After collection of blood in heparinised tubes, plasma was obtained from the blood samples as described in a 
previous report (Ogunlana et al., 2018). Plasma concentrations of aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), high density lipoprotein (HDL), low density lipoprotein (LDL), 
triglycerides and cholesterol were assayed using Randox test kit. Total protein was determined using Lowry method 
described by Noeman et al. [17]. 
Statistical Analysis 
Data were expressed as mean ± standard error of mean (SEM). Statistical analysis was done by one-way analysis 
of variance (ANOVA) using version 15.0 of Statistical Package for the Social Sciences (SPSS). The means of the 
groups treated with H. umbellata was compared with the least significant difference in the negative and normal control 
groups with the statistical significance carried out at the 95 % confidence limit. 
RESULTS 
In table 2, the high serum concentration of ALP, AST and ALT in the negative control was significantly (p<0.05) 
reduced when treated with H. umbellata and Silymarin with H. umbellata treated group showing a similar result to 
that of normal control group. There was no significant (p>0.05) change in TP concentrations across the groups. 
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TABLE 1. Organ weights 
Groups Kidney Spleen Heart Brain Intestine Liver 
1 0.86±0.04 0.58±0.04 0.52±0.06 1.32±0.17Y 3.73±0.72 3.49±0.10Y 
2 0.84±0.04 0.56±0.07 0.51±0.03 0.93±0.09* 3.97±0.52 4.08±0.17* 
3 0.92±0.04 0.60±0.03 0.46±0.03 0.98±0.06* 4.03±0.33 3.41±0.14Y 
4 0.92±0.02 0.65±0.03 0.43±0.03 0.94±0.02* 3.84±0.14 3.28±0.06Y 
5 0.80±0.02 0.54±0.02 0.49±0.02 1.06±0.07 4.06±0.51 3.17±0.07Y 
6 1.07±0.23 0.63±0.04 0.48±0.03 1.05±0.10 4.17±0.17 3.54±0.29Y 
Values are represented as mean ± standard error of mean (M±S.E). Values marked with * shows significant (p < 0.05) difference 
from the normal group, Y shows significant (p< 0.05) difference from the negative group (CCl4 induced group). 
TABLE 2. Effects of H. umbellata on biochemical parameters 
Groups ALP (U/I) AST (U/I) ALT (U/I) TP (g/dl) 
1  703.80 ± 18.51Y  43.87±0.43Y  29.93±0.33Y  7.84±0.07 
2  1041.90 ±73.34*  58.01±0.61*  56.72±1.96*  7.59±0.81 
3  828.00± 83.25Y  47.25±3 .22Y  20.00±2.28*Y  8.55±0.56 
4  759±28.73Y  47.43± 0.51Y  26.24±4.61Y  6.60±1.09 
5  754.9±61.50Y  43.2±3.66Y  26.9±1.47*Y  8.33±0.67 
6  678.9±103.9Y  42.4±8.52*  25.7±1.03*Y  6.88±0.57 
Values are represented as mean ± standard error of mean (M±S.E). ALP, AST, ALT, TP represents alkaline phosphatase, 
aspartate aminotransferase, alanine aminotransferase, total protein. Values marked with * shows significant (p< 0.05) difference 
from the normal group, Y shows significant (p < 0.05) difference from the negative group (CCl4 induced group). 
 
Table 3 shows the effects of the plant extract on lipid profile. Concentration of HDL was significantly (p<0.05) 
reduced in the negative control with the effect reversed in H. umbellata and silymarin treated groups comparable to 
normal control. There was insignificant (p>0.05) increase in the concentrations of cholesterol and LDL in the H. 
umbellata treated groups, this was not comparable to normal control and silymarin treated group. In addition, the 
significant (p<0.05) increase in triglyceride concentration in negative control was reversed with H. umbellata and 
silymarin treatment. 
TABLE 3. Effects of H. umbellata on lipid profile 
Groups HDL(mmol/l)  LDL(mmol/l)  TRIG(mmol/l)  CHOL(mmol/l) 
1  2.6±0.23Y  4.57±1.44  0.43±0.10*Y  7.37±1.24 
2  0.91±0.25*  7.31±0.66  1.33±0.32  11.8±0.69 
3  2.91±0.50Y  5.94±1.09  0.33±0.17Y  9.00±1.41 
4  2.53±0.31Y  4.78±1.83  0.47±0.02Y 7.56±1.91 
5  3.68±0.69Y  8.95±1.71  0.55±0.21Y  12.9±1.59* 
6  2.17±0.28Y 11.2±3.23  0.63±0.14Y  13.6±2.96 
Values are represented as mean ± standard error of mean (M±S.E). HDL, LDL, TRIG, CHOL represents high density lipoprotein, 
low density lipoprotein, triglycerides, total cholesterol respectively. Values marked with * shows significant (p < 0.05) difference 
from the normal group, Y shows significant (p < 0.05) difference from the negative group (CCl4 induced group). 
DISCUSSION 
Increasing concentration of biochemical markers including alkaline phosphatase (ALP), alanine aminotransferases 
(ALT) and aspartate aminotransferases (AST) is indicative of liver damage caused by the administration of a 
xenobiotic such as CCl4. Transaminases are regarded to as enzymes of the cytoplasm and mitochondrial typically 
found in important body cells like the hepatocytes [18]. The two most important transaminases include ALT and AST. 
ALT however is a more specific enzyme to the liver. ALT catalyzes the reaction between L-alanine and α-ketoglutarate 
giving pyruvate and L-glutamate while AST catalyzes the reaction between L-aspartate and α-ketoglutarate producing 
oxaloacetate and L-glutamate [19]. Liver damage through necrosis or membrane dysfunction enables the release of 
liver function enzymes into circulation thus increasing their concentration in the serum and making them a reliable 
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marker for liver dysfunction [15]. This dysfunction could be as a result of oxidative stress induced by the CCl4 [20]. 
This study showed a result in line with the above explanation in which CCl4 treated groups showed a significant 
increase in transferases when compared to the normal control [21]. A cell membrane enzyme, ALP generally related 
to bone and hepatobiliary diseases is known to be found in cases of cholestasis and was also elevated in this study 
clearly indicating the disruption to the hepatic membrane of the hepatocytes from CCl4 exposure [22, 23, 24]. 
Treatment with seeds of H. umbellata ameliorated the damage caused by CCl4 in relation to ALP, AST and ALT 
which could be attributed to the safety of the plant on the liver as established by [25]. The relationship between these 
liver function enzymes and lipid metabolism cannot be overemphasized due to the role the liver plays in the latter. 
Impaired lipid metabolism is an expected consequence of CCl4 induced hepatotoxicity which is characterised by 
reduced high density lipoprotein (HDL) and increased low density lipoprotein (LDL), triglyceride (TRIG) and 
cholesterol (CHOL) levels. From the study, group 2, the CCl4–induced group showed a significant decrease in HDL 
level. However, there was increase in LDL, TRIG and CHOL which correlate with previous reports [26, 27]. This 
could be explained by an increased influx of acetate to the hepatocytes upon CCl4 administration thus leading to an 
increased production of fatty acids and triglycerides [28]. Seeds of H. umbellata reversed the effect of lipid metabolism 
dysfunction by increasing the plasma level of high density lipoprotein (HDL) and reducing the level of triglyceride. 
CONCLUSION 
It can be concluded that seeds of H. umbellata exhibited a hepatoprotective property due to its efficacy in 
normalising high density lipoprotein and triglyceride levels, as well as the activities of alkaline phosphatase, aspartate 
aminotransferase and alanine transaminase in damaged liver. However, its anticholesteremic activity could not be 
established in this study at the concentration tested. 
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